198 related articles for article (PubMed ID: 15771616)
1. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
2. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
4. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
[TBL] [Abstract][Full Text] [Related]
8. RET tyrosine kinase signaling in development and cancer.
Arighi E; Borrello MG; Sariola H
Cytokine Growth Factor Rev; 2005; 16(4-5):441-67. PubMed ID: 15982921
[TBL] [Abstract][Full Text] [Related]
9. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
[TBL] [Abstract][Full Text] [Related]
10. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
11. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
13. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
[TBL] [Abstract][Full Text] [Related]
14. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
15. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
16. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
17. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
18. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
19. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
20. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]